Diovan

Diovan is the brand name under which Novartis markets valsartan, an angiotensin II receptor blocker (ARB) used to treat hypertension, heart failure and post-myocardial-infarction patients. Launched by the Swiss pharmaceutical group in the 1990s, Diovan became one of the company's blockbuster cardiovascular franchises and one of the most widely prescribed ARBs worldwide, sold in tablet form under the Diovan name and combined with hydrochlorothiazide as Diovan HCT. The brand is a prescription pharmaceutical product rather than a consumer product line; it is distributed through pharmacies and healthcare systems in dozens of markets and is typically prescribed as a once-daily oral therapy. Diovan's commercial peak came in the 2000s, before generic valsartan competition eroded sales after patent expiry in major markets. Novartis continues to hold the trademark and supplies Diovan-branded products in markets where the brand remains active. The brand sits within Novartis's cardiovascular portfolio alongside other legacy medicines, and its history is closely tied to the broader ARB class that replaced older antihypertensive therapies. Because Diovan is a medicine, its public profile is shaped by clinical guidance, regulatory approvals and pharmacovigilance events — notably the global valsartan impurity recalls of 2018, which affected many manufacturers of the active ingredient, including some Diovan-related supply chains. The brand remains a recognizable name in cardiovascular medicine and a standard example of a pharmaceutical trademark built on a single molecule.

Diovan was developed by Ciba-Geigy and continued under Novartis after the 1996 merger of Ciba-Geigy and Sandoz that created Novartis. Valsartan, the active molecule, was one of the first angiotensin II receptor blockers to reach the market, arriving after losartan and competing in a fast-growing class of antihypertensive drugs that offered better tolerability than ACE inhibitors. Marketed as Diovan, the product was approved for hypertension and later for heart failure and post-myocardial-infarction use, and Novartis extended the franchise with Diovan HCT, a fixed-dose combination with the diuretic hydrochlorothiazide. During the 2000s Diovan became one of Novartis's largest-selling medicines and a cornerstone of its primary-care cardiovascular portfolio, generating multi-billion-dollar annual sales at its peak. Patent protection expired in major markets in the early 2010s, opening the door to generic valsartan and sharply reducing branded revenue; Novartis nonetheless retained the trademark and continued to supply Diovan in certain countries. The brand's later history was overshadowed by the 2018 global recalls of valsartan active ingredient contaminated with nitrosamine impurities, which triggered regulatory action across many markets and reinforced scrutiny of pharmaceutical supply chains. Diovan remains a recognized prescription brand in cardiovascular care, though its commercial role has shifted as generics dominate the molecule.

• Novartis formed through the merger of Ciba-Geigy and Sandoz, inheriting the valsartan development program.

• Diovan (valsartan) launched as a branded ARB for hypertension.

• Diovan HCT fixed-dose combination with hydrochlorothiazide introduced.

• Diovan becomes one of Novartis's top-selling medicines during the 2000s.

• Patent expiry in major markets opens the molecule to generic competition in the early 2010s.

• Global valsartan nitrosamine impurity recalls affect supply chains across markets in 2018.

Prescription cardiovascular brand (ARB class) marketed by Novartis to physicians and health systems.

• Diovan (valsartan) tablets

  Once-daily oral angiotensin II receptor blocker for hypertension and heart failure.

• Diovan HCT

  Fixed-dose combination of valsartan and hydrochlorothiazide for hypertension.

• 2026

  Novartis recalls Diovan valsartan batch over dissolution specification failure

  Novartis recalled a specific batch of its Diovan (valsartan) blood pressure drug after it failed to meet dissolution specifications, potentially reducing effectiveness. The FDA classified the notice as a Class II recall, warning of possible temporary or medically reversible adverse health consequences. The affected batch, marked AV5913C, consists of 90-count 160-mg tablets expiring June 2027, manufactured by Pantheon Manufacturing Services in Greenville, North Carolina and distributed nationwide in the US.

  Source

Read more

• 2026.08.04

  Reported2026.08.13

  Novartis recalls Diovan valsartan batch over dissolution specification failure[1]Novartis recalls Diovan valsartan batch over dissolution specification failureaol.co.uk

  Novartis recalled a specific batch of its Diovan (valsartan) blood pressure drug after it failed to meet dissolution specifications, potentially reducing effectiveness. The FDA classified the notice as a Class II recall, warning of possible temporary or medically reversible adverse health consequences. The affected batch, marked AV5913C, consists of 90-count 160-mg tablets expiring June 2027, manufactured by Pantheon Manufacturing Services in Greenville, North Carolina and distributed nationwide in the US.

Read more

1. 1Novartis recalls Diovan valsartan batch over dissolution specification failureaol.co.uk